Selected Publications

Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. Transplant Cell Ther. Nov 2022.

Pratz KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M.: A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica Oct 2022.

Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD.: Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clin Cancer Res Aug 2022.

Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW.: Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol 2022.

Konopleva, M., Thirman, M. J., Pratz, K. W., Garcia, J. S., Recher, C., Pullarkat, V., Kantarjian, H. M., DiNardo, C. D., Dail, M., Duan, Y., Chyla, B., Potluri, J., Miller, C. L., Wei, A. H.: Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res 2022.

Jonas, B. A., Wei, A. H., Recher, C., DiNardo, C. D., Jang, J. H., Pratz, K., Panayiotidis, P., Montesinos, P., Yeh, S. P., Ivanov, V., Fiedler, W., Yamauchi, T., Duan, Y., Mendes, W., Potluri, J., Tews, B., Ofran, Y.: Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 2022.

Hatch, R. V., Freyer, C. W., Carulli, A., Redline, G., Babushok, D. V., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K. W., Stadtmauer, E. A., Loren, A. W.: Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. J Oncol Pharm Pract 28(4): 892-897, 2022.

Graveno, M. E., Carulli, A., Freyer, C. W., Mangan, B. L., Nietupski, R., Loren, A. W., Frey, N. V., Porter, D. L., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Babushok, D. V., Pratz, K. W.: Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Leuk Lymphoma Page: 1-6, 2022.

Freyer, C. W., Carulli, A., Gier, S., Ganetsky, A., Timlin, C., Schuster, M., Babushok, D., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Mangan, J. K., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K., Smith, J., Stadtmauer, E. A., Loren, A. W.: Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. Leuk Lymphoma Page: 1-9, 2022.

Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA.: Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 2022.